Patent 11839689
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Active provider: Google · gemini-2.5-flash
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Astellas US LLC, Medivation AG, Astellas Pharma Inc, Medivation Prostate Therapeutics LLC
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Proceedings overview
There are no AIA trial proceedings on file for US patent 11,839,689 as of the most recent ingest from the USPTO ODP API. Therefore, there is no PTAB activity to report.
Strategic summary
As of today's date, May 30, 2026, all claims of US patent 11,839,689 remain untested by any AIA trial proceeding. This means that if a defendant is facing assertion of this patent, all claims are currently presumed valid from a PTAB perspective.
Since there are no PTAB proceedings, there is no estoppel landscape to consider under 35 U.S.C. § 315(e)(2). All prior-art grounds remain available for a potential petitioner.
The absence of PTAB activity for a patent involved in ongoing litigation, as detailed in the "Litigation summary" section, is notable. Well-asserted patents often become targets for IPRs or other AIA trials.
Recommended next steps
If you are a defendant facing assertion of US patent 11,839,689, it is important to note the lack of PTAB activity. This means the patent's claims have not been challenged before the PTAB. Considering the ongoing district court litigation, an analysis of potential prior art for an IPR or PGR filing could be a viable defensive strategy, as no estoppel would apply from previous PTAB proceedings.
Generated 5/30/2026, 6:46:27 PM